at13148
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2012 (NCT01585701)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
MAPKAPK2 inhibitor
- Rho-associated protein kinaseINHIBITOR
Rho-associated protein kinase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1- Mol. weight
- 313.79 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3544960 ↗
Also known as
- at13148
- at13148
- at-13148
- at-13148
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01585701 | Phase 1 | May 1, 2012 | Cancer Research UK |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cancer Research UK | Academic/Hospital | 1 | 1 | 1 | 2012 |
1 organizations
Page 1 / 1